| 영문 | Dilatation and Curettage(D & C) | 한글 | 자궁긁어냄술, 자궁목확장 |
|---|---|---|---|
| 설명 | 자궁이란 태아가 수태되어서 분만전까지 발육하고 성장하는 공간이다. 자궁속에 병변이 있어 임신이 계속될 수 없거나 아니면 다른 이유로 임신되어 있는 태아를 제거하고자 할 경우에 사용되는 방법이다. 여기서 긁어내기 위하여는 우선 자궁의 입구에 해당하는 자궁목을 확장시켜야 한다. 여기에는 급속히 확장을 시도하는 법과 서서히 확장을 시도하는 2가지 방법이 있다. 자궁목을 급속히 확장할 때는 헤가르 목관확장기(Hegar's dilatator)를 사용한다. 이것은 작은 금속막대로 작은 크기부터 큰 크기까지 다양한 크기가 있어서 우선 작은 막대로 시작하여 점점 큰 크기의 막대를 자궁목에 넣어서 자궁목을 확장시킨다. 서서히 확장시킬 때는 Laminaria tent를 목관에 삽입하는 방법을 사용한다. Laminaria tent란 해초로 만든 작은 막대로 수분을 흡수하면 점점 늘어나는 성질이 있다. 이것을 자궁의 목에 넣으면 이것이 수분을 흡수하여 늘어나므로 천천히 자궁의 목이 늘어난다. 자궁목이 충분히 늘어나면 그 속으로 끝이 숟가락처럼 생긴 기구를 넣어서 자궁속의 병변이나 임신된 태아를 긁어내는데 여기에 사용되는 숟가락처럼 생긴 기구를 큐렛이라고 한다. 초기 임신중절 즉 유산과 같은 임신과 관련된 경우뿐만 아니라, 비임신 자궁의 자궁내막조직의 채취 및 제거를 위해서도 행해지는 수기이다. 이는 원칙적으로 마취하에 실시되는 것으로 자궁목관을 확장하고 기구로 자궁 내용물을 제거하고 큐렛으로 자궁내벽을 깨끗이 한다. 자궁천공이나 자궁목의 파열 등의 위험이 따르며, 수술후 감염 또는 출혈 등에 대한 주의가 필요하다. |
||
| 영문 | injection | 한글 | 주입 |
|---|---|---|---|
| 설명 | 액체를 피하조직, 혈관, 또는 장기 등 어떤 부분에 밀어 넣는 것, 또는 그러한 방법으로 투여된 물질을 말한다. |
||
| TMP-SMX | trimethoprim-sulfamethaxole; trimethoprim-sulfamethoxazole |
|---|---|
| SULF-PRIM | sulfamethoxazole and trimethoprim |
| TMP/SMX | Trimethoprim-Sulfamethoxazole(= Bactrim) |
| SXT | sulfamethoxazole-trimethoprim [mixture] |
| TRM-SMX | trimethoprim-sulfamethoxazole |
| ST | Sulfamethoxazole-Trimethoprim |
|---|---|
| SMX-TMP | Sulfamethoxazole-trimethoprim |
| TMP-SMX | Trimethoprim Sulfamethoxazole |
| TMP-SMZ | Trimethoprim-Sulfamethoxazole |
| TS | Trimethoprim-Sulfamethoxazole |
| trimethoprim-sulfamethoxazole | A drug combination consisting of a dihydrofolate reductase inhibitor (trimethoprim) and a sulfonamide antibacterial drug (sulfamethoxazole). The drug combination is synergistic as the drugs interfere with two successive steps in the formation/utilization of folic acid by microorganisms. Used to treat many infectious diseases. (05 Mar 2000) |
|---|---|
| trimethoprim-sulfamethoxazole combination | <chemical> 4-amino-n-(5-methyl-3-isoxazolyl)benzenesulfonamide mixture with 5-((3,4,5-trimethoxyphenyl)methyl)- 2,4-pyrimidinediamine. This drug combination has proved to be an effective therapeutic agent with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including pneumocystis carinii pneumonia in aids, but is the drug of choice for urinary infection. Pharmacological action: anti-infective agents, anti-infective agents, urinary, antimalarials. Chemical name: Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)-, mixt. With 5-((3,4,5-trimethoxyphenyl)methyl)-2,4-pyrimidinediamine (12 Dec 1998) |
| sulfamethoxazole | <chemical> A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. Pharmacological action: anti-infective agents, Chemical name: Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)- (12 Dec 1998) |
| trimethoprim | <drug> A drug that inhibits the reduction of dihydrofolate to tetrahydrofolate (a later step than that inhibited by sulphonamides). Selective for some bacterial dihydrofolate reductases and often used in conjunction with sulphonamides. (19 Jan 1998) |
| trimethoprim resistance | Nonsusceptibility of a bacterium to the action of trimethoprim. (12 Dec 1998) |
| adrenal cortex injection | An obsolete treatment involving the parenteral administration of extract of the adrenal cortex; formerly used in treatment of Addison's disease. (05 Mar 2000) |
| bolus injection | <procedure> The injection of a drug (or drugs) in a high quantity (called a bolus) at once, the opposite of gradual administration (as in intravenous infusion). (18 Nov 1997) |
| regular insulin injection | A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma. Synonym: regular insulin injection. (05 Mar 2000) |
| Ringer's injection | A sterile solution of sodium chloride, potassium chloride, and calcium chloride, containing in each 100 ml between 820 and 900 mg of sodium chloride, between 25 and 35 mg of potassium chloride, and between 30 and 37 mg of calcium chloride; used intravenously as a fluid and electrolyte replenisher. (05 Mar 2000) |
| water for injection | Water purified by distillation for the preparation of products for parenteral use. (05 Mar 2000) |
| collagen injection | Correction of superficial soft tissue deformities, acne scars, or age-related skin changes by injection (implantation) of collagen; bovine collagen preparations are commonly used. Prior intradermal testing is necessary to exclude hypersensitivity. (05 Mar 2000) |
| selective injection | Injection of contrast medium following selective catheterization of a branch artery or vein for angiography. (05 Mar 2000) |
| sensitizing injection | An injection that sensitises a person so that subsequent exposure to the antigen (allergen) evokes an allergic response. (05 Mar 2000) |
| hypodermic injection | The administration of a remedy in liquid form by injection into the subcutaneous tissues. Synonym: hypodermic. (05 Mar 2000) |
| neutral beam injection | <radiobiology> This is one of the fundamental plasma heating methods. A particle accelerator is used to create fast ion beams (the particle energies are on the order of 100 keV), the ion beam is then passed through a neutral gas region, where the ions neutralise via charge-exchange reactions with the neutral gas. The neutralised beam is then injected into a magnetically confined plasma. The neutral atoms are unaffected (not confined) by the magnetic field, but ionize as they penetrate into the plasma. The high-energy ions then transfer some of their energy to the plasma particles in repeated collisions, and heat the plasma. (09 Oct 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|